ACIP Presentation Slides: June 21-23, 2023 Meeting

Note: These files are not yet 508

Slides will be added as they become available.

June 21, 2023

Welcome & Introductions

• Introduction
  Dr. G Lee
  Dr. M Wharton

Respiratory Syncytial Virus Vaccines – Adult

• Introduction [8 pages]
  Dr. C Kotton
• Manufacturer presentation: Pfizer season 2 safety & efficacy; coadministration with influenza vaccine [21 pages]
  Dr. A Gurtman
• Manufacturer presentation: GSK season 2 safety & efficacy; coadministration with influenza vaccine [23 pages]
  Dr. L Friedland
• Updated cost-effectiveness of the Pfizer and GSK vaccines (main CDC model) [34 pages]
  Dr. D Hutton
• Comparison of cost effectiveness results of the main CDC model and each manufacturer model (Pfizer & GSK) [27 pages]
  Dr. I Ortega Sanchez
• Updated EtR (incl. GRADE) for 2 vaccines (Pfizer & GSK) [88 pages]
  Dr. M Melgar
• Clinical considerations for 2 vaccines (Pfizer & GSK) [12 pages]
  Dr. A Britton

Polio Vaccine

• Introduction [2 pages]
  Dr. O Brooks
• Recommendations for Adult Polio Vaccination [75 pages]
  Dr. S Kidd

Influenza Vaccines

• Introduction [5 pages]
  Dr. K Talbot
• WG considerations [86 pages]
  Dr. L Grohskopf
• Proposed Recommendations [16 pages]
  Dr. L Grohskopf

June 22, 2023

Welcome & Introductions

• Introduction
  Dr. G Lee
  Dr. M Wharton

Pneumococcal Vaccines

• Introduction [13 pages]
  Dr. K Poehling
• Economic analysis and public health impact of PCV20 use in children [33 pages]
  Dr. C Stoecker
• Comparison of cost-effectiveness analyses on PCV20 use in children [44 pages]
  Dr. D Ayabina
• Summary of WG interpretation on EtR and policy options [77 pages]
  Dr. M Kobayashi

Dengue Vaccines

• Introduction [8 pages]
  Dr. W Chen
• Introduction of policy questions for TAK-003 [8 pages]
  Dr. A Hernandez
• Cost effectiveness analysis and health impacts of routine vaccination with TAK-003 dengue vaccine in Puerto Rico [26 pages]
  Dr. G Espana
• Summary of two economic models for dengue vaccine TAK-003 use in Puerto Rico [30 pages]
  Dr. R Kaul
• Partial EtR framework for TAK-003 [65 pages]
  Dr. J Wong

Chikungunya Vaccine

• Introduction [6 pages]
  Dr. B Bell
• Value of chikungunya vaccine to U.S. travelers and providers [30 pages]
  Ms. N Lindsey
• Chikungunya virus infection among laboratory workers [9 pages]
  Dr. S Hills
• Update on large chikungunya outbreak in Paraguay [12 pages]
  Dr. S Hills
• Workgroup plans and timelines [4 pages]
  Dr. S Hills

Respiratory Syncytial Virus Vaccines – Pediatric/Maternal

• Introduction [6 pages]
  Dr. S Long
• Economic analysis of RSVpreF in pediatric populations [52 pages]
  Dr. D Hutton
• EtR Pfizer maternal RSV vaccine [130 pages]
  Dr. K Fleming-Dutra
• Economic analysis of combined use of nirsevimab and maternal RSVpreF vaccine [57 pages]
  Dr. D Hutton
• Clinical considerations for RSV maternal vaccine and nirsevimab [11 pages]
  Dr. J Jones

June 23, 2023

Welcome & Introductions

• Introduction
  Dr. G Lee
  

Mpox Vaccine

• Introduction [17 pages]
  Dr. P Sanchez
• Updates From the 2022/2023 U.S. Mpox Outbreak: Epidemiology, Vaccine Safety, and Vaccine Effectiveness [35 pages]
  Dr. F Minhaj
• Use of JYNNEOS During Mpox Outbreaks: Clinical guidance [25 pages]
  Dr. A Rao
• Considerations for Long-term Protection Against Mpox [24 pages]
  Dr. A Rao

Meningococcal Vaccines

• Introduction [5 pages]
  Dr. K Poehling
• Cost effectiveness analysis [39 pages]
  Dr. I Ortega-Sanchez
• GRADE/EtR; Summary and workgroup considerations [85 pages]
  Dr. S Crow

Vaccine Safety

• Introduction [7 pages]
  Dr. T Shimabukuro
• The childhood immunization schedule and safety: Studies in the Vaccine Safety Datalink [20 pages]
  Dr. M Daley
• Preliminary evaluation of aluminum content in childhood vaccines and risk of asthma in a Danish nationwide cohort [12 pages]
  Dr. A Hviid

COVID-19 Vaccines

• Introduction [8 pages]
  Dr. M Daley
• Updates to COVID-19 epidemiology and vaccine effectiveness [62 pages]
  Dr. F Havers, Dr. R Galang, Dr. R Link-Gelles
• Infection-induced and hybrid immunity [14 pages]
  Dr. J Jones
• Summary and work group considerations [21 pages]
  Dr. M Wallace